Sedana Medical Q4: Beat us on sales and seems to return to acceleration - Redeye

Redeye notes that Sedana Medical’s Q4 report showed higher sales than our estimates, though EBITDA was fairly in line with our expectations. We believe Sedana Medical stands a chance to make a considerable return to growth during 2024, which could better point to its likelihood of success in the future US launch.

Länk till analysen i sin helhet: https://www.redeye.se/research/979557/sedana-medical-q4-beat-us-on-sales-and-seems-to-return-to-acceleration?utm_source=finwire&utm_medium=RSS